PMGC Holdings (NASDAQ: ELAB) has recently captured significant investor attention following the announcement of a second major aerospace and defense supply agreement. This strategic contract…
April 09, 2026
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has officially announced a significant technological advancement in its clinical development pipeline. The company is successfully developing a new, brain-penetrating…
Eli Lilly and Company (NYSE: LLY) recently achieved a landmark regulatory success with the FDA approval of Foundayo (orforglipron). This new oral treatment provides a…
BioHarvest Sciences Inc. (NASDAQ: BHST) has officially secured the top position in the United States resveratrol and polyphenol market. This milestone for BioHarvest Sciences reflects…
AbbVie Inc. (NYSE: ABBV) recently announced its new status as the official pharmaceutical partner of Major League Baseball. This multi-year agreement allows the pharmaceutical giant…
March 20, 2026
Johnson & Johnson Secures FDA Approval for Icotyde to Disrupt the Oral Psoriasis Market
Johnson & Johnson (NYSE: JNJ) recently reached a major regulatory milestone with the FDA approval of Icotyde for plaque psoriasis. By virtue of this approval,…
February 20, 2026
AstraZeneca Secures FDA Label Expansion for Calquence
AstraZeneca PLC (NYSE: AZN) recently expanded its oncology footprint on the New York Stock Exchange with a new regulatory victory. The U.S. Food and Drug…
February 12, 2026
Madrigal Signals MASH Monopoly with $4.4 Billion RNAi Pact
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is aggressively expanding its therapeutic footprint within the multi-billion dollar liver disease market. The company recently finalized a strategic licensing…
February 10, 2026
AbbVie Invests $100M to Future-Proof Domestic Drug Production
AbbVie (NYSE: ABBV) is prioritizing its domestic production capabilities through a series of multi-million dollar capital investments. The New York Stock Exchange-listed firm aims to…
January 22, 2026
Lexicon Pharmaceuticals Secures FDA Alignment for LX9211
Lexicon Pharmaceuticals (NASDAQ: LXRX) recently announced a major regulatory milestone regarding its lead clinical candidate, LX9211. The company successfully completed an End-of-Phase 2 meeting with…
January 12, 2026
AbbVie Inks $5.6B Bispecific Deal with RemeGen
AbbVie Inc. (NYSE: ABBV) is making a massive bet on the next generation of cancer treatment. The pharmaceutical giant recently signed an exclusive licensing agreement…
Rhythm Pharmaceuticals (NASDAQ: RYTM), Inc., a global biopharmaceutical company dedicated to improving the lives of patients with rare neuroendocrine diseases, announced the presentation of four…